Amyloid Pathology Is Associated with Progressive Monoaminergic Neurodegeneration in a Transgenic Mouse Model of Alzheimer's Disease

• DOI: 10.1523/jneurosci.4218-08.2008
• Publication Date: 2008-12-17T17:23:20Z
• Authors: Ying Liu; Mi-Jeong Yoo; Alena Savonenko; Wanda Stirling; Donald L. Price; David R. Borchelt; Laura Mamounas; W. Ernest Lyons; Mary E. Blue; Michael K. Lee
• Keywords: Monoaminergic; Forebrain; Tauopathy

β-Amyloid (Aβ) pathology is an essential pathogenic component in Alzheimer's disease (AD). However, the significance of Aβ pathology, including deposits/oligomers and glial reactions, to neurodegeneration unclear. In particular, despite neurotoxicity indicated by vitro studies, mouse models with significant deposition lack robust progressive loss forebrain neurons. Such results have fueled view that insufficient for vivo . this study, because monoaminergic (MAergic) neurons show degenerative changes at early stages AD, we examined whether APPswe/PS1 Δ E9 model recapitulates MAergic occurring AD cases. We progression associated losses afferents. Significantly, axonal degeneration atrophy cell bodies eventually leads (∼50%) subcortical Degeneration these occurs without obvious local or tau sites precedes onset anxiety-associated behavior mice. Our a transgenic develops